Tilray Stock Has Lost Most of Its Value - Does Diversification Change the Math?
Tilray Brands has shed more than 90% of its value over the past five years, with shares trading at just under $5. For cannabis investors who have been watching the company's trajectory, that number
A Multi-State Operator Files DEA Applications Under Cannabis Rescheduling Pathway
Ascend Wellness Holdings has moved to register its state-licensed medical cannabis dispensary operations with the U.S. Drug Enforcement Administration, filing applications under the expedited pathway
DEA Rescheduling Hearing Puts Cannabis Operators on Watch for Federal Tax Relief
The Drug Enforcement Administration opened a formal hearing on June 29 to consider moving marijuana from Schedule I to Schedule III under the Controlled Substances Act - a process set in motion by
DEA's Own Quality Standard May Complicate Marijuana Rescheduling for State-Licensed Products
A federal regulation that has gone largely unnoticed in the marijuana rescheduling debate is now being placed front and center - and it raises questions that neither the DEA nor state cannabis
Prohibitionists Sue to Block Federal Cannabis Rescheduling, Complicating Operator Planning
A legal challenge filed Monday by two anti-cannabis organizations is targeting the rescheduling order that moved state-licensed medical marijuana products from Schedule I to Schedule III of the
DEA Rescheduling Splits Cannabis Tax Law in Two, Reshaping Business Deductions
On April 22, 2026, the Drug Enforcement Administration issued a final order moving specific marijuana products from Schedule I to Schedule III of the Controlled Substances Act - and the downstream